284 related articles for article (PubMed ID: 24480547)
1. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.
Parmar S; Liu X; Tung SS; Robinson SN; Rodriguez G; Cooper LJ; Yang H; Shah N; Yang H; Konopleva M; Molldrem JJ; Garcia-Manero G; Najjar A; Yvon E; McNiece I; Rezvani K; Savoldo B; Bollard CM; Shpall EJ
Cytotherapy; 2014 Jan; 16(1):90-100. PubMed ID: 24480547
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
3. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
4. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
5. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
6. Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials.
McKenna DH; Sumstad D; Kadidlo DM; Batdorf B; Lord CJ; Merkel SC; Koellner CM; Curtsinger JM; June CH; Riley JL; Levine BL; Miller JS; Brunstein CG; Wagner JE; Blazar BR; Hippen KL
Cytotherapy; 2017 Feb; 19(2):250-262. PubMed ID: 27887864
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
[TBL] [Abstract][Full Text] [Related]
8. Suppressive Characteristics of Umbilical Cord Blood-derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells.
Vanichapol T; Pongsakul N; Srisala S; Apiwattanakul N; Chutipongtanate S; Hongeng S
J Immunother; 2019 May; 42(4):110-118. PubMed ID: 30921263
[TBL] [Abstract][Full Text] [Related]
9. Increased induction of allogeneic-specific cord blood CD4+CD25+ regulatory T (Treg) cells: a comparative study of naïve and antigenic-specific cord blood Treg cells.
Chang CC; Satwani P; Oberfield N; Vlad G; Simpson LL; Cairo MS
Exp Hematol; 2005 Dec; 33(12):1508-20. PubMed ID: 16338494
[TBL] [Abstract][Full Text] [Related]
10. Suppressor function of umbilical cord blood-derived CD4+CD25+ T-regulatory cells exposed to graft-versus-host disease drugs.
Porter SB; Liu B; Rogosheske J; Levine BL; June CH; Kohl VK; Wagner JE; Miller JS; Blazar BR
Transplantation; 2006 Jul; 82(1):23-9. PubMed ID: 16861937
[TBL] [Abstract][Full Text] [Related]
11. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cell supported umbilical cord blood ex vivo expansion enhances regulatory T cells and reduces graft versus host disease.
Fan X; Gay FP; Ong SY; Ang JM; Chu PP; Bari S; Lim TK; Hwang WY
Cytotherapy; 2013 May; 15(5):610-9. PubMed ID: 23419678
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo selection of recipient-type alloantigen-specific CD4(+)CD25(+) immunoregulatory T cells for the control of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Trenado A; Fisson S; Braunberger E; Klatzmann D; Salomon BL; Cohen JL
Transplantation; 2004 Jan; 77(1 Suppl):S32-4. PubMed ID: 14726768
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
[TBL] [Abstract][Full Text] [Related]
16. Human LAP
Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
[TBL] [Abstract][Full Text] [Related]
17. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells.
Liu X; Robinson SN; Setoyama T; Tung SS; D'Abundo L; Shah MY; Yang H; Yvon E; Shah N; Yang H; Konopleva M; Garcia-Manero G; McNiece I; Rezvani K; Calin GA; Shpall EJ; Parmar S
Bone Marrow Transplant; 2014 Jun; 49(6):793-9. PubMed ID: 24710569
[TBL] [Abstract][Full Text] [Related]
18. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
19. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
20. Expansion of natural killer cell receptor (CD94/NKG2A)-expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit.
Tanaka J; Sugita J; Kato N; Toubai T; Ibata M; Shono Y; Ota S; Kondo T; Kobayashi T; Kobayashi M; Asaka M; Imamura M
Exp Hematol; 2007 Oct; 35(10):1562-6. PubMed ID: 17681668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]